Workflow
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC ImmuneAC Immune(US:ACIU) Newsfilter·2025-04-02 10:00

Core Insights - AC Immune SA announced further positive interim results from the Phase 2 VacSYn clinical trial for ACI-7104.056, an active immunotherapy for early Parkinson's disease, highlighting safety and immunogenicity data [1][2] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's disease [6] - The company utilizes two clinically validated technology platforms, SupraAntigen® and Morphomer®, to develop a diversified pipeline of therapeutic and diagnostic programs [6] Clinical Trial Details - The VacSYn trial is an adaptive, placebo-controlled, biomarker-based Phase 2 study involving over 30 patients, with a treatment ratio of 3:1 for ACI-7104.056 versus placebo [2][4] - No serious adverse events related to the study drug have been reported, with mild and transient injection site reactions and headaches being the most common adverse events [2][7] Immunogenicity Results - Interim results indicate that ACI-7104.056 induced a more than 20-fold increase in anti-alpha-synuclein antibodies compared to placebo after four immunizations [3][7] - The antibody response was effectively boosted with each additional immunization, supporting the potential for increased antibody titers [7] Future Plans - Based on further interim results expected later in 2025, AC Immune may initiate Part 2 of the VacSYn trial with up to 150 patients, focusing on the progression of motor and non-motor symptoms and identifying disease-specific biomarkers [4]